Clinical outcome and economic impact of aminoglycoside peak concentrations in febrile immunocompromised patients with hematologic malignancies

Clinical Chemistry

Volumn 44, Issue 2, 1998, Pages 408-414

  Binder, Lutz ^a   Schiel, Xaver ^a   Binder, Claudia ^a   Almeida Menke, Fernandes Cristina ^a   Schüttrumpf, Silke ^a   Armstrong, Victor W ^a   Unterhalt, Michael ^a   Erichsen, Norbert ^a   Hiddemann, Wolfgang ^a   Oellerich, Michael ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; GENTAMICIN; TOBRAMYCIN; UREIDOPENICILLIN;

ADULT; AGED; CONFERENCE PAPER; CONTROLLED STUDY; COST CONTROL; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; FEVER; HEALTH CARE COST; HUMAN; IMMUNE DEFICIENCY; INFECTION; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUTROPENIA; NURSING; OTOTOXICITY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 15644367993     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.2.408     Document Type: Conference Paper

References (30)

1. Destache CJ, Meyer SK, Bittner MJ, Hermann KG. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. Ther Drug Monit 1990;12: 419-26.
2. Bertino JS Jr, Rodvold KA, Destache CJ. Cost considerations in therapeutic drug monitoring of aminoglycosides. Clin Pharmacokinet 1994;26:71-81.
3. Destache CJ, Meyer SK, Rowley KM. Does accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis. Ther Drug Monit 1990;12:427-33.
4. Bootman JL, Wertheimer AI, Zaske D, Rowland C. Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: a cost-benefit analysis. J Pharm Sci 1979;68: 268-72.
5. Preskorn SH, Fast FA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 1991;52(6, Suppl):23-33.
6. Davey PG, Parker SE, Orange G, Malek M, Dodd T. Prospective audit of costs and outcome of aminoglycoside treatment and of therapy for gram-negative bacteremia. J Antimicrob Chemother 1995;36:561-75.
7. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-32.
8. Behre G, Schedel I, Nentwig B, Wormann B, Essink M, Hiddemann W. Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins. Antimicrob Agents Chemother 1992;36:2139-46.
9. Link H, Maschmeyer G, Hiddemann W, Stille W, Meyer P, Helmerking M, Adam D. Interventional antimicrobial therapy in febrile neutropenic patients. Study group of the Paul Ehrlich Society for Chemotherapy. Ann Hematol 1994;69:231-43.
10. Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161:381-96.
11. Meyer P, Adam D, Hiddemann W, Link H, Maschmeyer G, Helmerking M. Interventionstherapie von Infektionen und Fieber unklarer Genese bei neutropenischen Patienten mit malignen hämatologischen Grunderkrankungen. Studie II. Z Antimikr Antineoplast Chemother 1992;10:1-27.
12. Barnes RA, Rogers TR. Response rates to a staged antibiotic regimen in febrile neutropenic patients. J Antimicrob Chemother 1988;22:759-63.
13. Klastersky J, Glauser MP, Schimpff SC, Zinner SH, Gaya H. Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother 1986; 29:263-70.
14. Brown AE. Neutropenia, fever, and infection. Am J Med 1984;76: 421-8.
15. McQuaker IG, Hunter AE, Pacey S, Haynes AP, Iqbal A, Russell NH. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lympnoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 1997;15:451-7.
16. Messori A, Trippoli S, Tendi E. G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic outcome. J Clin Pharm Ther 1996;21: 57-63.
17. Faulds D, Lewis N, Milne RJ. Recombinant granulocyte colony stimulating factor: pharmacoeconomic considerations m chemotherapy-induced neutropenia. Pharmacoeconomics 1992;1:231-49.
18. Glaspy JA, Bleecker G, Crawford J, Stoller R, Strauss M. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer 1993;29A(Suppl 7):S23-30.
19. Leese B, Collin R, Clark DJ. The costs of treating febrile neutropenia in patients with malignant blood disorders. Pharmacoeconomics 1994;6:233-9.
20. Cimino MA, Rotstein CM, Moser JE. Assessment of cost-effective antibiotic therapy in the management of infections in cancer patients. Pharmacoeconomics 1994;28:105-11.
21. Leese B. The costs of treating febrile neutropenia in six U.K. hospitals. Eur J Cancer 1993;29A(Suppl 7):S15-8.
22. Malik IA, Khan WA, Aziz Z, Karim M. Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms. Clin Infect Dis 1994; 19:522-7.
23. Bash RO, Katz JA, Cash JV, Buchanan GR. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 1994;74:189-96.
24. Rubenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante C, Manzullo E, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993;71: 3640-6.
25. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994;12:107-14.
26. Mitchell PL, Morland B, Stevens MC, Dick G, Easlea D, Meyer LC, Pinkerton CR. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 1997;15:1163-70.
27. Jolicoeur LM, Jones-Grizzle AJ, Boyer JG. Guidelines for performing a pharmacoeconomic analysis. Am J Hosp Pharm 1992;49:1741-7.
28. Zaske DE, Bootman JL, Solem LB, Strate RG. Increased burn patient survival with individualized dosages of gentamicin. Surgery 1982;91:142-9.
29. Noone P. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J 1974;i: 477-81.
30. Moore RD. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984;149:443-8.